The U.S. Food and Drug Administration is increasingly relying on expedited approvals of drugs that skip or shorten test trials. This is a departure from past practice, when most drugs for serious illnesses were given greater scrutiny before being allowed to enter the market.

Source: Peter Loftus, “Fast-Track Drug Approval, Designed for Emergencies, Is Now Routine,” The Wall Street Journal, July 5, 2019, https://tinyurl.com/yycoqw8z

Data for the graphic are as follows:

Year Percentage of Expedited Approvals
2009 38%
2010 52%
2011 57%
2012 56%
2013 48%
2014 66%
2015 60%
2016 73%
2017 61%
2018 73%

close window